Gilead Sciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Daniel O'Day
- Full Time Employees
- 17,600
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 333 Lakeside Drive Foster City CA United States of America 94404
- IPO Date
- Jan 22, 1992
- CIK
- 0000882095
- Website
- gilead.com
- Similar Companies
- Business
- Gilead Sciences, Inc. (Nasdaq: GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need, with primary focus areas including HIV/AIDS, viral hepatitis, oncology, inflammation and serious respiratory diseases. The company markets a portfolio of marketed products such as Biktarvy, Descovy, Truvada and Veklury for virology; Epclusa, Vosevi and Vemlidy for liver diseases; Trodelvy, Tecartus and Yescarta for oncology; and investigational assets across its therapeutic areas, including complete regimen single-tablet treatments for HIV, nucleotide reverse transcriptase inhibitors and NS5A/NS5B inhibitors for hepatitis C. Founded in 1987 and headquartered in Foster City, California, Gilead operates globally with facilities across North America, Europe (including international headquarters in Stockley Park, UK), Asia-Pacific (such as Japan, China and Australia) and approximately 17,000 employees worldwide. Recent strategic developments include a $32 billion U.S. investment commitment by 2030 to expand manufacturing and R&D capabilities, highlighted by the September 2025 groundbreaking of a new Pharmaceutical Development and Manufacturing Technical Development Center in Foster City projected to create thousands of jobs; an up-to-$400 million acquisition in November 2025 of Sprint Bioscience's preclinical TREX1 oncology immunotherapy program; a $350 million buyout in August 2025 of Interius BioTherapeutics by subsidiary Kite Pharma to advance in vivo CAR-T cell therapies for cancer; a January 2025 strategic partnership with LEO Pharma acquiring rights to preclinical oral STAT6 inhibitors and targeted protein degraders for inflammatory diseases; and an expanded agreement with Cognizant in early 2025 to enhance productivity through advanced technologies.
Can Gilead Sciences HIV Franchise Drive Long-Term Growth?
Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead
Baron Discovery Fund Q1 2026: Who Moved The Needle
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands
Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH?
GILD Reports Positive Results From Late-Stage Liver Disease Study
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome
Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
Gilead Sciences, Inc. (GILD) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1--1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)